The NFKB1 Knockout Raji Polyclonal Cells consist of a heterogeneous population of human Raji B lymphocytes engineered using CRISPR/Cas9-mediated gene disruption to ablate NFKB1 expression. This polyclonal knockout pool, derived from an Epstein-Barr virus (EBV)-positive Burkitt??s lymphoma line, serves as a robust loss-of-function model for investigating NF-??B signaling in a lymphomagenic context. Unlike clonal derivatives, the polyclonal nature preserves cellular heterogeneity, enabling studies that better reflect population-level responses and reducing clonal selection artifacts often associated with single-cell-derived knockout lines.
Raji cells are an extensively characterized human B-lymphocyte line originally established from a Burkitt??s lymphoma patient. They maintain features of germinal center B cells, including EBV latency type III, which drives constitutive activation of several signaling modules, including NF-??B. This background provides a physiologically relevant system for examining the role of NFKB1 in B-cell lymphoma biology, as the interplay between viral oncoproteins and host transcription factors is central to tumor maintenance and immune evasion.
The NFKB1 gene encodes the p105 precursor, which is processed to the p50 subunit of the NF-??B transcription factor family. p50 can form repressive homodimers or transcriptionally active heterodimers with RELA, RELB, or c-REL. Activation of canonical NF-??B signaling by TNF-??, CD40 ligand, or B-cell receptor engagement leads to IKK complex (IKBKB, CHUK, IKBKG)-mediated phosphorylation and degradation of I??B?? (NFKBIA), releasing NF-??B dimers to translocate to the nucleus and induce target genes such as IL6, TNF, BCL2, BCL2L1, and CCND1. NFKB1 knockout removes p50 from these complexes, disrupting both repressive and activating functions and reshaping cellular responses to immune and inflammatory stimuli.
In the Raji lymphoma context, NFKB1 is critical for sustaining the pro-survival and proliferative programs driven in part by EBV latency products. The absence of p50 impairs p50/RELA heterodimer formation, attenuating induction of anti-apoptotic BCL2 and BCL2L1, and the cell cycle regulator CCND1. These polyclonal knockout cells exhibit diminished activation of downstream targets upon TNF-?? or B-cell receptor stimulation and increased sensitivity to apoptosis, making them a valuable model for dissecting NF-??B-driven oncogenesis in EBV+ lymphomas.
Researchers can employ these cells in Western blotting for NF-??B subunits and phospho-I??B??, EMSA for DNA binding, RT-qPCR (e.g., IL6, BCL2), flow cytometry for apoptosis (Annexin V), NF-??B luciferase reporter assays, and cell proliferation studies (MTS). Applications include investigating NF-??B??s role in B-cell lymphoma, screening NF-??B pathway inhibitors, evaluating CRISPR off-target effects, and modeling immunodeficiency. For further details, contact Ascent Research.
